EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Kosei Hasegawa iD, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J Monk, Krishnansu S Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil und 13 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70236 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kosei Hasegawa und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐line platinum‐based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan.

Methods

Patients were enrolled regardless of programmed cell death‐ligand 1 status and randomized 1:1 to cemiplimab 350 mg intravenously every 3 weeks or investigator's choice single‐agent chemotherapy for up to 96 weeks. Primary endpoint was OS. Key secondary endpoints were progression‐free survival (PFS) and objective response rate (ORR).

Results

Overall, 608 patients were randomized, of whom 56 (9.2%) were in Japan (cemiplimab, n = 29; chemotherapy, n = 27). The median (range) duration of follow‐up was 13.6 (6.0–25.3) versus 18.2 (6.0–38.2) months for patients in Japan and for the overall population, respectively. Median OS (95% confidence interval [CI]) was 8.4 (7.0‐not evaluable) and 9.4 (5.4–14.9) months for cemiplimab versus chemotherapy (hazard ratio [HR]: 0.86; 95% CI: 0.43–1.68). Median PFS (95% CI) was 4.0 (1.4–8.2) versus 3.7 (1.8–4.2) months with cemiplimab and chemotherapy (HR: 0.90; 95% CI: 0.50–1.61), respectively. ORR was 17.2% for cemiplimab and 7.4% for chemotherapy (odds ratio, 2.47; 95% CI, 0.44–13.99). Incidence of treatment‐emergent adverse events at any grade was 79.3% for cemiplimab and 100% for chemotherapy. Grade ≥3 adverse events were 37.9% versus 66.7% with cemiplimab and chemotherapy, respectively.

Discussion

While acknowledging limitations inherent to a small subgroup analysis, the HR of 0.86 observed in Japanese patients suggests an emerging survival benefit despite a 4.6‐month shorter median duration of follow‐up versus the overall study population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalHumansFemaleMiddle AgedAdultAgedJapanProgression-Free SurvivalAntineoplastic Agents, ImmunologicalEast Asian People

Stichwörter der Autor:innen

cemiplimabcervical cancerchemotherapyimmunotherapyprogrammed cell death‐1

Substanzen

Antibodies, Monoclonal, HumanizedcemiplimabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
  • Gynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Saitama Cancer Center, Saitama, Japan.

ORCID-Profile: Kosei Hasegawa, Kazuhiro Takehara

Förderung

  • Sanofi
  • Regeneron Pharmaceuticals

Zitieren

APA

Hasegawa, K., Takahashi, S., Ushijima, K., Okadome, M., Yonemori, K., Yokota, H., Vergote, I., Monk, B. J., Tewari, K. S., Fujiwara, K., Li, J., Jamil, S., Paccaly, A., Takehara, K., Usami, T., Aoki, Y., Suzuki, N., Kobayashi, Y., Yoshida, Y., …, & Oaknin, A. (2024). Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70236

Vancouver

Hasegawa K, Takahashi S, Ushijima K, Okadome M, Yonemori K, Yokota H, et al. Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70236

BibTeX
@article{Hasegawa2024,
  author = {Hasegawa, Kosei and Takahashi, Shunji and Ushijima, Kimio and Okadome, Masao and Yonemori, Kan and Yokota, Harushige and Vergote, Ignace and Monk, Bradley J and Tewari, Krishnansu S and Fujiwara, Keiichi and Li, Jingjin and Jamil, Shaheda and Paccaly, Anne and Takehara, Kazuhiro and Usami, Tomoka and Aoki, Yoichi and Suzuki, Nao and Kobayashi, Yoichi and Yoshida, Yoshio and Watari, Hidemichi and Seebach, Frank and Lowy, Israel and Mathias, Melissa and Fury, Matthew G and Oaknin, Ana},
  title = {Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70236}
}
Kostenlos starten →